US Court Confirms Sandoz Skirted Amgen’s Chromatography Patent

 
• By Aidan Fry

Sandoz’ approved filgrastim, and pending pegfilgrastim, biosimilars do not infringe a US patent held by Amgen, the US Court of Appeals has confirmed in a ruling that also warns against regularly asserting infringement under the doctrine of equivalents.  

Chemistry
Amgen's US purification patent based on chromatography is not infringed by Sandoz' G-CSF products • Source: Shutterstock

More from Biosimilars

More from Products